Internalizing moieties for treatment of cancer
AssigneeValerion Therapeutics, LLC
InventorDustin D. Armstrong
Life of this patent
Estimating the term…
Abstract
In certain embodiments, the present disclosure provides compositions and methods for treating tumors and cancer.
Claims22
A method of treating a tumor in a subject in need thereof, comprising administering an antibody or antigen-binding fragment to the subject, wherein the antibody or antigen-binding fragment comprises a light chain variable (VL) domain and a heavy chain variable (VH) domain;
- wherein the VH domain comprises:
- a VH CDR1 having the amino acid sequence of SEQ ID NO:
- 1;
- a VH CDR2 having the amino acid sequence of SEQ ID NO:
- 2;
- and
- a VH CDR3 having the amino acid sequence of SEQ ID NO:
- 3,
- which CDRs are according to the IMGT system;
- or
- wherein the VH domain comprises:
- a VH CDR1 having the amino acid sequence of SEQ ID NO:
- 32;
- a VH CDR2 having the amino acid sequence of SEQ ID NO:
- 49;
- and
- a VH CDR3 having the amino acid sequence of SEQ ID NO:
- 34,
- which CDRs are according to the Kabat system;
- and the VL domain comprises:
- a VL CDR1 having the amino acid sequence of SEQ ID NO:
- 35 or 50;
- a VL CDR2 having the amino acid sequence of SEQ ID NO:
- 51;
- and
- a VL CDR3 having the amino acid sequence of SEQ ID NO:
- 37,
- which CDRs are according to the Kabat system,
- wherein the antibody binds DNA with a KD of less than 100 nM and promotes transit across cellular membranes via an equilibrative nucleoside transporter 2 (ENT2) transporter.
A method of inhibiting proliferation of a cancerous cell or tumor cell, comprising contacting the tumor cell with an antibody or antigen-binding fragment, wherein the antibody or antigen-binding fragment comprises a light chain variable (VL) domain and a heavy chain variable (VH) domain;
- wherein the VH domain comprises:
- a VH CDR1 having the amino acid sequence of SEQ ID NO:
- 1;
- a VH CDR2 having the amino acid sequence of SEQ ID NO:
- 2;
- and
- a VH CDR3 having the amino acid sequence of SEQ ID NO:
- 3,
- which CDRs are according to the IMGT system;
- or
- wherein the VH domain comprises:
- a VH CDR1 having the amino acid sequence of SEQ ID NO:
- 32;
- a VH CDR2 having the amino acid sequence of SEQ ID NO:
- 49;
- and
- a VH CDR3 having the amino acid sequence of SEQ ID NO:
- 34,
- which CDRs are according to the Kabat system;
- and the VL domain comprises:
- a VL CDR1 having the amino acid sequence of SEQ ID NO:
- 35 or 50;
- a VL CDR2 having the amino acid sequence of SEQ ID NO:
- 51;
- and
- a VL CDR3 having the amino acid sequence of SEQ ID NO:
- 37,
- which CDRs are according to the Kabat system,
- wherein the antibody binds DNA with a KD of less than 100 nM and promotes transit across cellular membranes via an equilibrative nucleoside transporter 2 (ENT2) transporter.
A method of decreasing Ki-67 or CD31 expression in a tumor, comprising contacting the tumor cell with an antibody or antigen-binding fragment, wherein the antibody or antigen-binding fragment comprises a light chain variable (VL) domain and a heavy chain variable (VH) domain;
- wherein the VH domain comprises:
- a VH CDR1 having the amino acid sequence of SEQ ID NO:
- 1;
- a VH CDR2 having the amino acid sequence of SEQ ID NO:
- 2;
- and
- a VH CDR3 having the amino acid sequence of SEQ ID NO:
- 3,
- which CDRs are according to the IMGT system;
- or
- wherein the VH domain comprises:
- a VH CDR1 having the amino acid sequence of SEQ ID NO:
- 32;
- a VH CDR2 having the amino acid sequence of SEQ ID NO:
- 49;
- and
- a VH CDR3 having the amino acid sequence of SEQ ID NO:
- 34,
- which CDRs are according to the Kabat system;
- and the VL domain comprises:
- a VL CDR1 having the amino acid sequence of SEQ ID NO 35 or 50;
- a VL CDR2 having the amino acid sequence of SEQ ID NO 51;
- and
- a VL CDR3 having the amino acid sequence of SEQ ID NO:
- 37,
- which CDRs are according to the Kabat system,
- wherein the antibody binds DNA with a KD of less than 100 nM and promotes transit across cellular membranes via an equilibrative nucleoside transporter 2 (ENT2) transporter.
Dependencies are inferred from the claim text.